Mainstream

AstraZeneca beats top-line and bottom-line estimates; reaffirms FY25 outlook

AstraZeneca beats top-line and bottom-line estimates; reaffirms FY25 outlook

Post Contentazn, azncfRead More

You might also be interested in reading Bitcoin Price Smashes $61.7K High — Leading Crypto Asset Needs to Gain Over 5% to Reach ATH.

July 29, 2025
In Mainstream